Registration successful
Account activated – pending validation.
Your account has been activated successfully, but we still need to validate you as a healthcare professional. We’ll send you an email with the result of the validation process in the next [five] days.
In the meantime, you can enjoy access to all the latest news, events and resources on our website
Combodart reduces prostate volume and, therefore, causes a decrease in serum PSA levels by approximately 50% after 6 months in patients with BPH.[1]
Patients receiving Combodart should have a new PSA baseline established after 6 months of treatment. It is recommended to monitor PSA values regularly thereafter.[1]
Any confirmed increase from lowest PSA level while on Combodart should be carefully evaluated as it may signal the presence of prostate cancer or non-compliance to therapy with Combodart.[1]
PSA levels in BPH patient receiving Combodart (schematic representation):[1]
Treatment with dutasteride does not interfere with the use of PSA as a tool to assist in the diagnosis of prostate cancer after a new baseline has been established. [1]
Additional checks on treatment compliance or other factors that can affect PSA values should be considered in the interpretation of results.[1]
Please refer to the SPC for full information on how to monitor PSA levels in patients receiving Combodart.
* Prostate-Specific Antigen
References:
- Combodart Prescribing Information available at www.medicines.ie, last accessed May 2018
Adverse events should be reported directly to the HPRA; Freepost, Pharmacovigilance Section, Health Products Regulatory Authority, Earlsfort Terrace, Dublin 2, Tel: +353 1 676 4971 medsafety@hpra.ie. Adverse events should also be reported to GlaxoSmithKline on 1800 244 255.
Combodart is registered trademark of the GlaxoSmithKline Group of companies
